-
Asabys-backed Oriva Therapeutics launches to advance novel treatments for women’s health
Read more: Asabys-backed Oriva Therapeutics launches to advance novel treatments for women’s health• Oriva Therapeutics is launched with the support of Asabys, focused on developing innovative therapies in women’s health• The company incorporates two advanced assets from Oncostellae and Medibiofarma, addressing two…
-
Medibiofarma Successfully Completes Phase 2A Clinical Trial of MBF-118 for Fibrotic Crohn’s Disease
Read more: Medibiofarma Successfully Completes Phase 2A Clinical Trial of MBF-118 for Fibrotic Crohn’s DiseaseNavarra, Spain – August 28, 2025 — Medibiofarma is pleased to announce the successful completion of the industrial research project titled “Investigation of Novel Agonists of the PPAR-γ Receptor for the…
-
Medibiofarma Receives 2nd Funding Award from the Crohn’s & Colitis Foundation to Support Development of a New Antifibrotic Therapy
Read more: Medibiofarma Receives 2nd Funding Award from the Crohn’s & Colitis Foundation to Support Development of a New Antifibrotic TherapyCrohn’s & Colitis Foundation’s IBD Ventures Awards Investment to Continue their Support for the Development of Medibiofarma’s Novel First-In-Class PPARg Partial Agonist Oral Therapy (MBF-118) for Treatment of Crohn’s Disease…
-
Palobiofarma and Medibiofarma open new headquarters in the AINbuilding in Cordovilla, Spain
Read more: Palobiofarma and Medibiofarma open new headquarters in the AINbuilding in Cordovilla, SpainPalobiofarma and Medibiofarma open new headquarters in the AINbuilding in Cordovilla, Spain · The new facilities, of 200 square meters, consist of an office area next to a fully equipped…
-
Medibiofarma S.L. announced the award of the European CommissionSeal of Excellence for their clinical asset MBF-015.
Read more: Medibiofarma S.L. announced the award of the European CommissionSeal of Excellence for their clinical asset MBF-015.Navarra – February 2025 – Medibiofarma S.L., a clinical-stage biotechnology company developinga portfolio of new small molecule therapies announced the award of the European CommissionSeal of Excellence for their clinical…
-
First patient dosed in the Phase IIa clinical trial of MBF-015 in patients with Huntington’s disease
Read more: First patient dosed in the Phase IIa clinical trial of MBF-015 in patients with Huntington’s diseaseNavarra – February 2024 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of neurodegenerative diseases and other pathologies announced the first patient…
-
MEDIBIOFARMA announced the first patient dosed in the Phase IIa clinical trial of MBF-118 in patients with Crohn’s disease.
Read more: MEDIBIOFARMA announced the first patient dosed in the Phase IIa clinical trial of MBF-118 in patients with Crohn’s disease.Navarra – May 10, 2023 – Medibiofarma S.L., a clinical-stage biotechnology company developing aportfolio of new therapies for the treatment of gastrointestinal (GI) diseases as well as othercancer and non-cancer…
-
Medibiofarma Receives Funding from the Crohn’s & Colitis Foundation to Support Development of a New Antifibrotic Therapy for Inflammatory Bowel Disease
Read more: Medibiofarma Receives Funding from the Crohn’s & Colitis Foundation to Support Development of a New Antifibrotic Therapy for Inflammatory Bowel DiseaseCrohn’s & Colitis Foundation’s IBD Ventures Awards Investment to Support Development of Medibiofarma’s Novel First-In-Class PPARg Partial Agonist Oral Therapy (MBF-118) for Treatment of Crohn’s Disease Pamplona, Spain / March 3, 2023 / Medibiofarma, a biopharmaceutical company developing…
-
MEDIBIOFARMA ANNOUNCES FIRST SUBJECT DOSED IN MBF-015 PHASE I CLINICAL STUDY: New HDAC1/2 inhibitor in healthy volunteers
Read more: MEDIBIOFARMA ANNOUNCES FIRST SUBJECT DOSED IN MBF-015 PHASE I CLINICAL STUDY: New HDAC1/2 inhibitor in healthy volunteersNavarra – July 2021– Medibiofarma S.L., a clinical-stage biotechnology company developing, as part of its portfolio of projects, a new disease-modifying therapy for the treatment of neurodegeneration and cognitive decline…
-
Medibiofarma announces first subject dosed in phase Ib multiple ascending dose study of MBF-118, a new PPARg covalent partial agonist, in healthy volunteers
Read more: Medibiofarma announces first subject dosed in phase Ib multiple ascending dose study of MBF-118, a new PPARg covalent partial agonist, in healthy volunteersNavarra – July 2021– Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of cancer and non-cancer diseases today announced the first subject dosed…
